LetterLETTERS TO THE EDITOR
Open Access

Reply to “Comment on ‘Pneumocystis jirovecii Pneumonia in Patients Treated for Solid Organ Malignancy’ ”

Ian Jackson, Raul Isern, Stephanie Jesina, Manasa Velagapudi and William Pruett
Ochsner Journal September 2024, 24 (3) 168; DOI: https://doi.org/10.31486/toj.24.5047

TO THE EDITOR

We thank Khan and Ahmad1 for their interest in our case series, “Pneumocystis jirovecii Pneumonia in Patients Treated for Solid Organ Malignancy.”2

We agree that the increasing use of dose-dense chemotherapy regimens makes this clinical situation an important issue. We also agree with the recommendations outlined in their letter—namely that further study of the true incidence of Pneumocystis jirovecii pneumonia in this population is warranted and that raising clinician awareness of the heightened risk of Pneumocystis jirovecii pneumonia can help with early recognition and management.

On behalf of all the authors, please accept our appreciation for the letter.

©2024 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

REFERENCE

  1. 1.↵
    1. Khan S,
    2. Ahmad B
    . Comment on “Pneumocystis jirovecii pneumonia in patients treated for solid organ malignancy.” Ochsner J. 2024;24(3). doi: 10.31486/toj.24.0088
    OpenUrlFREE Full Text
  2. 2.↵
    1. Jackson I,
    2. Isern R,
    3. Jesina S,
    4. Velagapudi M,
    5. Pruett W
    . Pneumocystis jirovecii pneumonia in patients treated for solid organ malignancy. Ochsner J. 2024;24(3). doi: 10.31486/toj.24.0024
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section